Oncolytics Biotech Inc. (NASDAQ: ONCY): Why We Have All Eyes On It Early This Morning

*Sponsored Just Announced! Oncolytics Biotech Inc. (NASDAQ: ONCY) is Our Next Potential Breakout Idea For Today… And Here’s Why… Targeting $116B Markets: Focused on oncology markets projected to surpass $116B by 2034, including breast, pancreatic, and stomach cancers. Analyst Coverage: HC Wainwright & Co. reaffirmed a $5 target for Oncolytics Biotech Inc. (NASDAQ: ONCY), which suggests a 525% potential upside. Major Collaborations: Partnerships with Roche, Pfizer, and leading academic institutions boost research and development efforts. 2025 Milestones: Key data releases and regulatory advancements planned across multiple cancer indications. Keep reading to see why we have all eyes on Oncolytics Biotech Inc. (NASDAQ: ONCY) this morning… January 22, 2025 Dear Reader, If you’re not paying attention to Oncolytics Biotech Inc. (NASDAQ: ONCY) this morning, you could be missing out on one of the most exciting developments in oncology today.  Oncolytics Biotech Inc. (NASDAQ: ONCY) isn’t just part of the cancer treatment revolution—they’re leading it.  With groundbreaking research, industry-shaking collaborations, and a pipeline that’s redefining expectations, Oncolytics Biotech Inc. (NASDAQ: ONCY) is rewriting the rules and showing the world what innovation truly looks like. We have all eyes on Oncolytics Biotech Inc. (NASDAQ: ONCY) this morning as it takes the #1 position on our watchlist today.  In fact, a little over two months ago, on 11/14, Benzinga reported that HC Wainwright & Co., one of Wall Street’s oldest institutions, had reiterated a $5.00 target on Oncolytics Biotech Inc. (NASDAQ: ONCY).   This target suggests an upside potential of 525% from yesterday’s $.80 open. Now keep reading to see why we’re so excited about Oncolytics Biotech Inc. (NASDAQ: ONCY). Let’s start with the showstopper: the BRACELET-1 study.  This isn’t your average clinical trial. It’s a bold statement in the fight against HR+/HER2- metastatic breast cancer, proving that pelareorep, Oncolytics Biotech Inc. (NASDAQ: ONCY)’s groundbreaking immunotherapy is no ordinary treatment. Median Overall Survival (OS): Patients treated with pelareorep + paclitaxel achieved survival rates nearly double those on paclitaxel alone. Progression-Free Survival (PFS): The pelareorep combination extended PFS to 12.1 months compared to 6.4 months for paclitaxel monotherapy. Safety Profile: Remarkably strong, even in patients who had undergone extensive prior treatments. These results build on the earlier IND-213 study, further cementing pelareorep’s reputation as a game-changing therapy.  With the FDA already showing alignment on progression-free survival as a primary endpoint, Oncolytics is gearing up for a registration-enabling study targeting approximately 55K U.S. patients who urgently need better options. GOBLET Study: A Multi-Cancer Offensive Oncolytics Biotech Inc. (NASDAQ: ONCY) isn’t stopping at breast cancer.   Their GOBLET study is a full-scale attack on gastrointestinal cancers, tackling some of the toughest cases in oncology.  Conducted across 17 centers in Germany, this Phase 1/2 trial is exploring pelareorep’s potential in combination therapies for: 1st line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) 1st line MSI-high metastatic colorectal cancer 3rd line metastatic colorectal cancer 2nd line or later unresectable anal cancer Newly diagnosed metastatic PDAC The study’s design is as ambitious as its scope, and early results are turning heads. With Germany’s Paul-Ehrlich-Institute (PEI) giving the green light for Cohort 5 to move to full enrollment, Oncolytics is charging forward with confidence. Cohort 5: A Paradigm Shift in Pancreatic Cancer Pancreatic cancer is one of the most challenging diseases to treat, but Oncolytics Biotech Inc. (NASDAQ: ONCY) isn’t backing down.  Cohort 5 of the GOBLET study is evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®).  Here’s what makes this trial so exciting: Positive Safety Review: The independent Data Safety Monitoring Board (DSMB) has already endorsed the safety profile, allowing the study to advance to full enrollment. Innovative Design: Blood and tumor samples are being collected for translational evaluations, ensuring a deeper understanding of pelareorep’s impact. Upcoming Data: Early safety results will debut at the 2025 ASCO GI Symposium, with efficacy results expected later in the year. “Pelareorep has the potential to meaningfully improve outcomes for patients with metastatic pancreatic cancer,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics Biotech Inc. (NASDAQ: ONCY). The results could mark a turning point in how this aggressive cancer is treated. Targeting Markets Worth Over $116B Oncolytics Biotech Inc. (NASDAQ: ONCY) is setting its sights on markets projected to exceed $116 bn within the next decade.  With its innovative approach and focus on transformative therapies, the company is strategically positioned to address some of the largest and fastest-growing segments in oncology: Global Breast Cancer Market: Reached $34.63B in 2024, growing to $38.06B in 2025, and predicted to surpass $89.01B by 2034. Global Stomach Cancer Treatment Market: Estimated at $6.08B in 2025 and expected to reach approximately $17.60B by 2034. Global Pancreatic Cancer Market: Accounted for $2.86B in 2024, increasing to $3.25B in 2025, and forecasted to hit $10.25B by 2034. By developing and advancing pelareorep, a groundbreaking immunotherapy, Oncolytics Biotech Inc. (NASDAQ: ONCY) is positioning itself to make a significant impact on these massive markets, meeting the unmet needs of patients worldwide. Partnering with Powerhouses Oncolytics Biotech Inc. (NASDAQ: ONCY) understands the value of teamwork, and they’ve partnered with some of the biggest names in the industry. The company is dedicated to advancing the development of pelareorep through partnerships with both industry and academic leaders. In the pharmaceutical world, Oncolytics Biotech Inc. (NASDAQ: ONCY) has teamed up with Roche Holding AG, Pfizer Inc., Merck Serono, Incyte Corporation, and Adlai Nortye to evaluate pelareorep in combination with therapeutic agents. On the academic front, Oncolytics has collaborated with the Mayo Clinic, Duke University, the Rutgers Cancer Institute of New Jersey, the Ohio State University Comprehensive Cancer Center, the Keck School of Medicine of the University of Southern California, PrECOG, SOLTI, and AIO-Studien-gGmbH to evaluate additional pelareorep-based combinations. Their collaboration with Roche on the GOBLET study brings unparalleled expertise to the table, while their alliance with the Global Coalition for Adaptive Research (GCAR) is a strategic masterstroke. GCAR’s innovative trial designs promise to accelerate timelines and reduce costs, giving Oncolytics a major competitive edge. 2025: The Year of Oncolytics Biotech Inc. (NASDAQ: ONCY) Here’s what Oncolytics Biotech Inc. (NASDAQ: ONCY) has on deck for 2025: H1 2025: Submit the GCAR-led adaptive registration-enabling trial protocol for first-line PDAC to the FDA. H1 2025: Present safety run-in data from GOBLET Cohort 5 at ASCO GI. H1 2025: Release updated efficacy data for GOBLET Cohort 4 in anal cancer. H2 2025: Share initial efficacy results from GOBLET Cohort 5. H2 2025: Enroll the first patient in the registration-enabling breast cancer study. Pelareorep And The Future of Immunotherapy Pelareorep isn’t just a treatment; it’s a revolution in the making. With its ability to convert “cold” tumors to “hot” ones, making them more susceptible to immune responses, this therapy is unlike anything we’ve seen before.  Its versatility across multiple cancer types and its proven efficacy make it a force to be reckoned with in the oncology world. Oncolytics Is Just Getting Started Oncolytics Biotech Inc. (NASDAQ: ONCY) isn’t here to play by the rules—they’re here to rewrite them. With trailblazing research, top-tier collaborations, and a relentless drive to innovate, they’re proving that cancer treatment doesn’t have to be business as usual.  Pelareorep is more than a therapy; it’s a beacon of hope, and its journey could be just the beginning.  7 Reasons Why We Have All Eyes On Oncolytics Biotech Inc. (NASDAQ: ONCY)  This Morning… 1. Analyst Coverage: HC Wainwright & Co. recently reiterated a $5 target for Oncolytics Biotech Inc. (NASDAQ: ONCY), suggesting 525% in upside potential. 2. Targeting Markets Worth Over $116B : The company is focused on oncology markets projected to exceed $116B by 2034, including breast, pancreatic, and stomach cancers. 3. Breakthrough Results: The BRACELET-1 study demonstrated pelareorep nearly doubling overall survival (OS) and significantly extending progression-free survival (PFS) in HR+/HER2- metastatic breast cancer. 4. Bold Approach to Pancreatic Cancer: The GOBLET study's Cohort 5 has advanced to full enrollment with promising safety reviews, targeting one of the hardest-to-treat cancers. 5. Innovative Clinical Trial Strategies: Oncolytics Biotech Inc. (NASDAQ: ONCY) leverages GCAR’s cutting-edge trial designs to accelerate development timelines and reduce costs. 6. Collaborations with Industry Giants: Partnerships with Roche, Pfizer, and leading academic institutions strengthen Oncolytics Biotech Inc. (NASDAQ: ONCY)’s research and development capabilities. 7. A Packed 2025 Agenda: Oncolytics Biotech Inc. (NASDAQ: ONCY) plans key data releases and regulatory advancements, highlighting their progress across multiple cancer indications. Consider Taking a Look at Oncolytics Biotech Inc. (NASDAQ: ONCY) While It’s Still Early… With HC Wainwright & Co. backing a $5 target, breakthrough clinical results, and a focus on $116B worth of markets, Oncolytics Biotech Inc. (NASDAQ: ONCY) is grabbing attention where it counts.  With collaborations alongside industry titans like Roche and a packed 2025 agenda, we have all eyes on (ONCY) today.  Take a closer look while it’s still early—we’ll be covering (ONCY) today, so keep an eye out for my next update.  I’ll check back with you shortly! Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/ *Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 01/21/2025 and ending on 01/22/2025 to publicly disseminate information about (ONCY:US) via digital communications. Under this agreement, we have been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither TD Media LLC or its member owns shares of (ONCY:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/oncy/

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice